These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15341779)

  • 21. American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.
    Bertino JS; Greenberg HE; Reed MD;
    J Clin Pharmacol; 2007 Apr; 47(4):418-22. PubMed ID: 17389550
    [No Abstract]   [Full Text] [Related]  

  • 22. International Symposium on Clinical Pharmacology. Introduction.
    Smahel O
    Int Z Klin Pharmakol Ther Toxikol; 1970 Dec; 4(1):3-5. PubMed ID: 4924327
    [No Abstract]   [Full Text] [Related]  

  • 23. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 24. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.
    Zhang R; Monsma F
    Expert Opin Drug Discov; 2010 Nov; 5(11):1023-9. PubMed ID: 22827742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
    Dorne JL
    Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The US drug safety system: role of the pharmaceutical industry.
    Gibson BR; Suh R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Some aspects on drug safety control].
    Pekkarienen A
    Nord Med; 1967 Nov; 78(47):1539-42. PubMed ID: 6075273
    [No Abstract]   [Full Text] [Related]  

  • 28. Medication use in the elderly: a population at risk.
    Loughran S
    Medsurg Nurs; 1996 Apr; 5(2):121-4. PubMed ID: 8704785
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug assays in the assessment of the clinical value and safety of new compounds.
    Campbell DB
    Contemp Issues Clin Biochem; 1985; 3():33-60. PubMed ID: 3915972
    [No Abstract]   [Full Text] [Related]  

  • 30. A comprehensive approach for drug safety assessment.
    Li AP
    Chem Biol Interact; 2004 Nov; 150(1):27-33. PubMed ID: 15522259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction: Human metabolites in safety testing (MIST) issue.
    Guengerich FP
    Chem Res Toxicol; 2009 Feb; 22(2):237-8. PubMed ID: 19216576
    [No Abstract]   [Full Text] [Related]  

  • 32. Avoiding adverse drug reactions in the elderly.
    Hershey LA
    Mt Sinai J Med; 1988 May; 55(3):244-50. PubMed ID: 3041268
    [No Abstract]   [Full Text] [Related]  

  • 33. Optimizing drug development and use in patients with kidney disease.
    Nolin TD; Arya V; Sitar DS; Pfister M
    J Clin Pharmacol; 2011 May; 51(5):628-30. PubMed ID: 21525394
    [No Abstract]   [Full Text] [Related]  

  • 34. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
    Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
    Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharma's year of trouble and strife.
    Frantz S
    Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
    [No Abstract]   [Full Text] [Related]  

  • 36. Adolescents in clinical trials.
    Kapogiannis BG; Mattison DR
    Clin Pharmacol Ther; 2008 Dec; 84(6):655-9. PubMed ID: 19008903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What happened to the modeling and simulation revolution?
    Bonate PL
    Clin Pharmacol Ther; 2014 Oct; 96(4):416-7. PubMed ID: 25236664
    [No Abstract]   [Full Text] [Related]  

  • 38. Laboratory tests during clinical trials.
    Scand J Clin Lab Invest Suppl; 1989; 195():16-8. PubMed ID: 2799277
    [No Abstract]   [Full Text] [Related]  

  • 39. Multitargeted drugs: the end of the "one-target-one-disease" philosophy?
    Wermuth CG
    Drug Discov Today; 2004 Oct; 9(19):826-7. PubMed ID: 15381132
    [No Abstract]   [Full Text] [Related]  

  • 40. [Epidemiology and the pharmaceutical industry].
    Walker AM; García Rodríguez LA; Pérez Gutthann S
    Med Clin (Barc); 1992 Mar; 98(12):465-8. PubMed ID: 1573915
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.